On September 25, 2024 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, reported that Oren Gilad, Ph.D., President and Chief Executive Officer, will deliver a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, to take place virtually on Tuesday, October 1, 2024 (Press release, Aprea, SEP 25, 2024, View Source [SID1234646854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Company Webcast

The webcasted presentation will take place at 12:30pm ET on Tuesday, October 1, 2024. The webcast can be accessed by visiting the conference home page at View Source or directly at View Source The webcast will also be available for replay following the event.

1×1 Meetings

Management will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×[email protected] or register for the event at View Source